Related Experiment Video

Updated: Nov 18, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.3K

Targeting the Hippo Pathway in Prostate Cancer: What's New?

Kelly Coffey1

  • 1Solid Tumour Target Discovery Laboratory, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Cancers
|February 9, 2021
PubMed

Insights

The Hippo signalling pathway, involving YAP/TAZ, is a promising therapeutic target for prostate cancer (PC) due to its dysregulation and crosstalk with androgen receptor (AR) signalling, especially in therapy-resistant cases.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signalling

Background:

  • Prostate cancer (PC) treatment faces challenges with resistance to androgen receptor (AR)-targeting therapies.
  • The Hippo signalling pathway, crucial for organ size and cell dynamics, is increasingly recognized for its role in cancer.
  • The Hippo pathway components, including STK4/3, LATS1/2, YAP, and TAZ, regulate gene transcription and cellular processes.

Purpose of the Study:

  • To review the Hippo signalling pathway's components and their relevance to prostate cancer.
  • To highlight recent findings (last year) concerning the Hippo pathway.
  • To explore therapeutic potential of targeting the Hippo pathway in PC, considering AR signalling crosstalk.

Main Methods:

  • Literature review focusing on the Hippo signalling pathway and its role in prostate cancer.
  • Analysis of recent research (within the last year) on Hippo pathway components (STK4/3, LATS1/2, YAP, TAZ, TEAD).
  • Examination of the interplay between Hippo pathway and AR signalling in PC.

Main Results:

  • The Hippo pathway is dysregulated in PC through various mechanisms.
  • YAP/TAZ, key Hippo pathway effectors, can modulate AR activity and other transcription factors.
  • Recent findings underscore the Hippo pathway's significant role in PC progression and therapeutic resistance.

Conclusions:

  • The Hippo signalling pathway represents a promising novel therapeutic target for prostate cancer.
  • Understanding the crosstalk between Hippo and AR signalling is critical for developing effective PC treatments.
  • Further research into targeting YAP/TAZ and their associated transcription factors (TEAD) could yield new PC therapies.
Keywords:
Hippo pathwayYAP/TAZcell signallingprostate cancer

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.2K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.6K

Related Concept Videos

Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
8.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K